What are the normal reference ranges for thyroid‑stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) in an adult without known thyroid disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Normal Reference Ranges for Thyroid Function Tests in Adults

For adults without known thyroid disease, the normal reference ranges are: TSH 0.45–4.5 mIU/L, free T4 (FT4) typically 9–19 pmol/L (laboratory-specific), and free T3 (FT3) measurement is rarely needed for routine screening. 1

TSH (Thyroid-Stimulating Hormone)

  • The standard reference range for TSH is 0.45–4.5 mIU/L, representing the 2.5th to 97.5th percentile in disease-free populations 1
  • The geometric mean TSH in healthy individuals is approximately 1.4 mIU/L 1
  • TSH demonstrates high diagnostic accuracy with >98% sensitivity and >92% specificity for detecting thyroid dysfunction 1
  • TSH values exhibit substantial biological variation, with day-to-day fluctuations reaching up to 50% of the mean value and intra-day variation of approximately 40% 1

Age-Related Considerations for TSH

  • In individuals aged ≥80 years, approximately 12% have TSH >4.5 mIU/L without underlying thyroid disease, indicating that the standard reference range may be inappropriately low for elderly adults 1
  • The upper limit of normal TSH shifts upward with advancing age, potentially reaching 7.5 mIU/L in patients over 80 years 1

Free T4 (Free Thyroxine)

  • Normal FT4 ranges are laboratory-specific but typically fall between 9–19 pmol/L (or approximately 0.7–1.5 ng/dL in conventional units) 1
  • FT4 measurement is essential when TSH is abnormal to distinguish subclinical (normal FT4) from overt (abnormal FT4) thyroid dysfunction 1
  • The combination of normal TSH with normal FT4 definitively excludes both overt and subclinical thyroid dysfunction 1

Free T3 (Free Triiodothyronine)

  • Routine FT3 measurement is NOT recommended for initial thyroid screening in asymptomatic adults 1
  • FT3 testing has limited clinical utility, with T3 thyrotoxicosis representing a rare diagnosis (approximately 0.5% of newly diagnosed hyperthyroidism cases) 2
  • FT3 measurement is most useful only when TSH is suppressed (<0.01 mIU/L) and FT4 is normal or decreased, to distinguish T3 thyrotoxicosis from subclinical hyperthyroidism 2, 3

When FT3 Testing May Be Indicated

  • In patients with TSH <0.01 mIU/L and normal/low FT4, particularly in the outpatient setting where T3 thyrotoxicosis frequency is higher (34% vs 14% inpatient) 2
  • To evaluate for autonomous thyroid hormone production when TSH is markedly suppressed but FT4 remains normal 3
  • All patients with newly diagnosed T3 thyrotoxicosis had TSH <0.01 mIU/L, making this the appropriate threshold for reflex FT3 testing 2

Important Caveats About Reference Ranges

Factors Causing Transient Abnormalities

  • TSH can be transiently affected by acute illness, hospitalization, recent iodine exposure (e.g., CT contrast), certain medications, or recovery from thyroiditis 1
  • These physiological factors should be considered before interpreting isolated abnormal results 1
  • 30–60% of initially elevated TSH values normalize spontaneously on repeat testing, highlighting the importance of confirmation before initiating treatment 1

Biological Variation Data

  • For TSH: within-subject biological variation (CVI) is 22.3%, between-subject variation (CVG) is 26.6%, and reference change value (RCV) is -40.3% to +67.6% 4
  • For FT3: CVI is 4.4%, CVG is 9.2%, and RCV is -10.4% to +11.6% 4
  • For FT4: CVI is 5.1%, CVG is 8.2%, and RCV is -12.7% to +14.5% 4
  • Because thyroid function tests show high individuality (individuality index <0.6 for FT3 and FT4), serial monitoring using RCV is more appropriate than population-based reference ranges for individual patients 4

Clinical Interpretation Algorithm

For initial thyroid assessment:

  1. Measure TSH as the first-line screening test 1
  2. If TSH is abnormal, measure FT4 to distinguish subclinical from overt dysfunction 1
  3. Do NOT routinely measure FT3 unless TSH is <0.01 mIU/L with normal/low FT4 2
  4. Always confirm abnormal results with repeat testing after 3–6 weeks before making treatment decisions 1

References

Related Questions

What is the appropriate first‑line antithyroid medication and starting dose for an adult with overt hyperthyroidism (TSH 0.18 µIU/mL, free triiodothyronine 14.85 pg/mL, free thyroxine 20.65 ng/dL)?
When a low thyroid‑stimulating hormone (TSH) is identified, should the initial laboratory evaluation be a serum free thyroxine (free T4) measurement or a serum free triiodothyronine (free T3) measurement?
Can a patient with an intact thyroid gland have a Thyroid-Stimulating Hormone (TSH) level of zero with normal Free Triiodothyronine (Free T3) and Free Thyroxine (Free T4) levels?
What is the next thyroid test to order in a patient with low Thyroid-Stimulating Hormone (TSH) and free Thyroxine (T4) levels?
What to do with a patient on Tri Lo Milli (norgestimate and ethinyl estradiol) with elevated thyroxine levels but normal Thyroid-Stimulating Hormone (TSH) levels?
In an AIDS patient with three large necrotic ring‑enhancing brain lesions and EBV DNA detected in CSF, how does the anatomic location of the lesions affect the choice of biopsy target and subsequent treatment strategy?
What is the recommended dosing schedule of apremilast for an adult with moderate‑to‑severe plaque psoriasis, including titration, maintenance dose, and adjustments for renal or hepatic impairment?
Can Artane (trihexyphenidyl) be used to treat tardive dyskinesia?
What is the recommended treatment for methicillin‑resistant Staphylococcus aureus (MRSA) pneumonia with a transient episode of bacteremia?
What are the recommended treatment options for prostate cancer across low‑risk localized, intermediate‑risk localized, high‑risk localized, metastatic hormone‑sensitive, and metastatic castration‑resistant disease, taking into account the patient’s age, life expectancy, comorbid conditions, and personal preferences?
What is the recommended oral corticosteroid dose (mg per kilogram per day) and tapering schedule for extensive or rapidly progressive alopecia areata?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.